Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 15/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4645796 | 0.99 | CHRM1 (0.61) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL11904533 | 0.88 | CHRM1 (0.48) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL4645893 | 0.87 | CHRM1 (0.75) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL4647882 | 0.87 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| Hydrochloric Acid SCHEMBL4687919 | 0.86 | CHRM1 (0.74) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| Hydrochloric Acid SCHEMBL4646777 | 0.86 | CHRM1 (0.61) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL4648913 | 0.86 | CHRM1 (0.76) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL602217 | 0.85 | CHRM1 (0.48) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL602214 | 0.85 | CHRM1 (0.48) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL602213 | 0.85 | CHRM1 (0.48) | CHRM1CHRM2CHRM4CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288412-B2 | Psychological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | claimed |
| EP-1960389-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | claimed |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | claimed |
| EP-1960389-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-08-27 | — | — | EP | claimed |
| WO-2007036718-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | claimed |
| US-8288412-B2 | Psychological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288412-B2 | Psychological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288412-B2 | Psychological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| EP-1960389-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM2 2/4885CHRM4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.